Epidemiological Profile of IDH-Mutant Diffuse Gliomas Diagnosed in Brazil (2021)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective, non-interventional study conducted at multiple centers in Brazil. It will include patients aged 12 and older diagnosed with IDH-mutant diffuse glioma from 2021, using existing medical records. Data on epidemiology, pathology, treatments, toxicities, and outcomes will be entered into REDCap and analyzed by LACOG to describe real-world patterns. Participation involves no protocol-specific visits or treatment changes, and consent is obtained for living patients. Data handling follows ICH guidelines with audit-ready data and maintained confidentiality.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female patients (aged 12 years or older);
* Histologically confirmed diagnosis of diffuse glioma from 2021;
* Confirmed IDH mutation identified by IHC or PCR/NGS;
* Willing and able to provide written informed consent, applicable to living patients. In case of patients \<18 years of age, their legal guardians should provide an written informed consent

Exclusion Criteria:

Since the study is observational, there are no extensive Exclusion Criteria, but the following criteria excludes patients from the study to ensure data collected by be analyzed from a broader context and compared to other studies of this kind:

* Patients without medical record available (lost, empty or irretrievable clinical information).
* Living patients and/or legal guardians of patients \<18 years of age who did not accept or withdrew their consent from the study.

Where it's running

• Futtura Oncologia - Hub de Pesquisa Clínica
  Porto Alegre, Rio Grande do Sul, Brazil Recruiting
• IESG Instituto de Ensino da Saúde e Gestão
  Salvador, Estado de Bahia, Brazil Not yet recruiting
• Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel (Oncoclínicas)
  Salvador, Estado de Bahia, Brazil Not yet recruiting
• ÉTICA Clínica AMO - Assistência Multidisciplinar em Oncologia
  Salvador, Estado de Bahia, Brazil Not yet recruiting
• OncoStar Rede D'or DF
  Brasília, Federal District, Brazil Not yet recruiting
• Oncocentro de Minas Gerais (Oncoclínicas)
  Belo Horizonte, Minas Gerais, Brazil Not yet recruiting

Study contacts

• Principal investigator: Carolina Pêssoa — Instituto Nacional do Câncer
• Study coordinator: Project Manager
• Email: lacog0425@lacog.group
• Phone: +55 (51) 3384.5334

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Proton versus photon radiation for adults with primary brain tumors

  This trial will test whether proton beam radiation causes fewer long-term side effects than standard photon (X-ray) radiation in adults aged 18–70 with primary brain tumors who are expected to live more than five years.

  Recruiting Tata Memorial Centre · Mumbai · NCT06831461

• Glioma adaptive radiotherapy using an AI-driven dose plan

  This trial tests whether using AI to guide adaptive radiation can improve treatment for adults with diffuse gliomas.

  Recruiting Phase 2 Tata Memorial Centre · Mumbai, Maharatshtra · NCT06492486

• Using Chlorophyllin to Treat Brain Damage from Radiation in Glioma Patients

  This study is testing if Chlorophyllin can help glioma patients with brain damage from radiation feel better and improve their quality of life.

  Recruiting Phase 2 Tata Memorial Centre · Mumbai, Maharashtra · NCT06016452

• Investigating the effects of DFMO and AMXT 1501 on brain tumor metabolism

  This study is testing how two drugs, DFMO and AMXT 1501, can change the metabolism of brain tumors in patients after surgery.

  Recruiting Early Phase 1 Mayo Clinic · Rochester, Minnesota · NCT05717153

• Using 18F-fluciclovine PET-MRI to assess high-grade gliomas in children

  This study is testing a special imaging technique to see if it can help doctors tell the difference between real tumor growth and changes after treatment in children with high-grade brain tumors.

  Recruiting Early Phase 1 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT05553041

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.